Dianthus Therapeutics, Inc. (DNTH) Financial Statements
Dianthus Therapeutics, Inc. (DNTH) reported trailing twelve-month revenue of $1.9M (down 60.8% year on year) and net income of -$192.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$155.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DNTHDianthus Therapeutics, Inc.Follow DNTH — free
—
Price chart with a free account
- Market cap
- 4.3B
- P/E TTM
- —
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.01 | 0.00 | 0.00 | |
| Research & development | 0.03 | 0.08 | 0.15 | 0.18 | |
| Operating income | -0.05 | -0.10 | -0.18 | -0.22 | |
| Pre-tax income | -0.04 | -0.08 | -0.16 | -0.19 | |
| Income tax | 0.00 | 0.00 | 0.00 | — | |
| Net income | -0.04 | -0.08 | -0.16 | -0.19 | |
| Diluted EPS ($) | -8.45 | -2.55 | -4.20 | -3.43 | |
| Diluted shares (bn) | 0.005 | 0.033 | 0.039 | — |
USD billions · SEC XBRL
Dianthus Therapeutics, Inc. — questions
- What is Dianthus Therapeutics, Inc.'s revenue?
- $1.9M over the twelve months to 2026-06-30, down 60.8% year on year, from its 10-Q and 10-K filings.
- What is Dianthus Therapeutics, Inc.'s net income?
- -$192.2M over the twelve months to 2026-06-30.
- What is Dianthus Therapeutics, Inc.'s free cash flow?
- -$155.7M over the twelve months to 2026-06-30.
- What are Dianthus Therapeutics, Inc.'s diluted earnings per share?
- $-3.43 over the twelve months to 2026-06-30.
Every figure on this page comes from Dianthus Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.